Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

Table 3

Baseline demographics in RE-LY, ROCKET AF, and ARISTOTLE.

	RE-LY [13]			ROCKET AF [14]		ARISTOTLE [15]
	Dabigatran 110 mg BD	Dabigatran 150 mg BD	Warfarin	Rivaroxaban	Warfarin	Apixaban	Warfarin
	n = 6015	n = 6076	n = 6022	n = 7131	n = 7133	n = 9120	n = 9081
Female, %	35.7	36.8	36.7	39.7	39.7	35.5	35.0
Prior VKA use, %	50.1	50.2	48.6	62.3	62.5	57.1	57.2
Age, years^†	71.4	71.5	71.6	73	73	70	70
CrCl < 50 mL/min, %		19.4 (for whole study)		22.4	23.2	15.0	15.2
HF/low LVEF^††, %	32.3	31.8	31.9	62.6	62.3	35.5	35.4
Hypertension, %	78.8	78.9	78.9	90.3	90.8	87.3	87.6
Diabetes, %	23.4	23.1	23.4	40.4	39.5	25.0	24.9
Prior stroke/TIA, %	19.9	20.3	19.8	54.9^†††	54.6^†††	19.2	19.7
Prior MI, %	16.8	16.9	16.1	16.6	18.0	14.5	13.9
CHADS2 mean	2.1	2.2	2.1	3.5	3.5	2.1	2.1

BD: twice daily; CrCl: creatinine clearance; HF: heart failure; LVEF: left ventricular ejection fraction, MI: myocardial infarction; TIA: transient ischaemic attack; VKA: vitamin K antagonist.
^†Mean in RE-LY; median for ROCKET AF and ARISTOTLE.
^††≤ 35% in ROCKET AF; ≤40% for RE-LY and ARISTOTLE.
^†††Includes systemic embolism.